以替尼泊甙为主的化疗方案相伴放疗治疗小细胞肺癌

目的探讨替尼泊甙（ＶＭ－２６）为主的化疗方案相伴放疗治疗小细胞肺癌的临床疗效。方法５３例小细胞肺癌中，４８例选用ＶＭ－２６＋顺铂（ＤＤＰ）方案，ＶＭ－２６每天６０ｍｇ／ｍ２，ＤＤＰ每天２５ｍｇ／ｍ２，连用３天为一个疗程；另５例用卡铂取代ＤＤＰ，５００ｍｇ静脉滴注，１天完成。除第１个与第２个疗程化疗间隔４０天左右外，以后每４周重复１个疗程，共５个疗程。在第１个疗程化疗后１～４天内开始放射治疗。对局限期和广泛期患者分别照射不同的剂量和部位。结果局限期患者近期疗效为９７．８％［完全缓解（ＣＲ）为５３．３％，部分缓解（ＰＲ）为４４．８％］，１年和２年生存率分别为７７．１％（２７／３５）和４４％（１１／２５），中位生存期大于１８个月。广泛期患者近期疗效为７５％（ＣＲ２５％），一年生存率为３７．５％（３／８），中位生存期大于１１个月。结论以ＶＭ－２６为主的化疗方案相伴放疗是治疗小细胞肺癌的有效方案，可提高肿瘤的局部控制率。

CONCURRENT TENIPOSIDEWITH THORACIC RADIOTHERAPY IN SMALL CELL LUNG CANCER

PURPOSE To report the clinical results of teniposide (VM 26) combined with thoracic radiotherapy in the treatment of 53 cases of small cell lung cancer. METHODS Most cases were treated with VM 26 DDP,VM 26 60mg/m 2/d and DDP 25 mg/m 2/d, the consecutive treatment of 3 days was consideres as one course. Most patients were treated with 5 courses. Different radiation doses and radiation fields were performed for two clinical groups. RESULTS For the limited stage cases,the response rate reached 97 8% (CR53 5%, PR44 3%),and one and two years survival rates were 77 1% and 44% respectively. For the extensive stage cases,the response rates were 75% (CR25%,PR50%), and one and two years survival rates were 37 5% and 25% respectively. CONCLUSIONS The results indicated that teniposide combined with thoracic radiotherapy can be considered as an effective method for the treatment of small cell lung cancer.